BRIEF published on 05/31/2024 at 17:03, 1 year 11 months ago Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA FDA Approval Moderna Vaccine RSV MRESVIA
BRIEF published on 05/31/2024 at 17:03, 1 year 11 months ago Moderna reçoit l'approbation de la FDA américaine pour le vaccin contre le RSV mRESVIA Approbation De La FDA Moderne VRS MRESVIA Vaccin
PRESS RELEASE published on 05/31/2024 at 16:58, 1 year 11 months ago Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R) Moderna gains FDA approval for mRESVIA, a single-dose pre-filled syringe RSV vaccine for adults 60+ to prevent lower respiratory tract disease. Second mRNA product and breakthrough therapy designation FDA Approval Moderna RSV Vaccine MRNA MRESVIA
BRIEF published on 05/22/2024 at 13:05, 1 year 11 months ago Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting Clinical Trials Immunotherapy Moderna ASCO 2024 MRNA-4157
BRIEF published on 05/22/2024 at 13:05, 1 year 11 months ago Moderna annonce que les données seront présentées lors de l'assemblée annuelle 2024 de l'ASCO Immunothérapie Essais Cliniques Moderne ASCO 2024 ARNm-4157
PRESS RELEASE published on 05/22/2024 at 13:00, 1 year 11 months ago Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting Moderna to host an investor event via webcast on June 3 at 6:15 PM CDT. Abstracts on mRNA-4157 for ASCO Annual Meeting. Details on mRNA-4157 (V940) therapy development Webcast Moderna Investor Event MRNA-4157 Neoantigen Therapy
BRIEF published on 05/13/2024 at 13:05, 1 year 11 months ago Moderna Announces Participation in Key Investor Conferences Investor Conferences Healthcare Financial Markets Moderna Webcasts
BRIEF published on 05/13/2024 at 13:05, 1 year 11 months ago Moderna annonce sa participation à des conférences clés pour les investisseurs Marchés Financiers Soins De Santé Conférences Investisseurs Moderne Webdiffusions
PRESS RELEASE published on 05/13/2024 at 13:00, 1 year 11 months ago Moderna to Present at Upcoming Conferences in May/June 2024 Moderna, Inc. to participate in upcoming investor conferences, showcasing its leadership in mRNA medicine and innovative approach to disease treatment. Live webcasts available Investor Conferences Moderna Inc. MRNA Medicine Webcasts Disease Treatment
BRIEF published on 05/02/2024 at 12:35, 2 years ago Moderna Reports Q1 2024 Financial Performance and Strategic Progress Financial Results MRNA Technology Moderna RSV Vaccine Vaccine Development
Published on 05/12/2026 at 14:30, 6 hours 15 minutes ago Pathfinder Ventures Inc. Announces Conclusion of Financing and Intention to Launch New Private Placement
Published on 05/12/2026 at 14:30, 6 hours 15 minutes ago ACCESS Newswire Reports First Quarter 2026 Results
Published on 05/12/2026 at 13:50, 6 hours 55 minutes ago Polaris Renewable Energy Announces Approval of SO1 Agreement by FOMB
Published on 05/12/2026 at 13:30, 7 hours 15 minutes ago Silver X Mining Begins Trading on OTCQX, Expanding Access to U.S. Investors
Published on 05/12/2026 at 13:30, 7 hours 15 minutes ago Electric Metals Launches Preliminary Economic Assessment for North Star Manganese Project Downstream HPMSM and EMM Processing Facilities
Published on 05/12/2026 at 20:21, 23 minutes ago Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 1 hour 10 minutes ago AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 19:35, 1 hour 10 minutes ago 2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
Published on 05/12/2026 at 18:46, 1 hour 58 minutes ago LION E-Mobility Reports Q1 Results and Confirms Fiscal 2026 Outlook
Published on 05/12/2026 at 18:45, 2 hours ago Antitrust authority approval granted for the acquisition of a portfolio of rental units in Poland
Published on 05/12/2026 at 18:15, 2 hours 30 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 2 hours 30 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 2 hours 35 minutes ago imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 2 hours 35 minutes ago imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 2 hours 55 minutes ago Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités
